Literature DB >> 19968805

Changes in acid-base, electrolyte and hemoglobin concentrations during infusion of hydroxyethyl starch 130/0.42/6 : 1 in normal saline or in balanced electrolyte solution in children.

Robert Sümpelmann1, Lars Witt, Meike Brütt, Dirk Osterkorn, Wolfgang Koppert, Wilhelm A Osthaus.   

Abstract

INTRODUCTION: A balanced volume replacement strategy is a well established concept for correcting hypovolemia using plasma adapted isotonic crystalloid solutions with a physiological electrolyte pattern and acetate as bicarbonate precursor. Recently, third-generation hydroxyethyl starch (HES) has also become available in a balanced electrolyte solution instead of normal saline. Therefore, in this prospective non-interventional clinical study, the perioperative administration of HES 130/0.42/6 : 1 in normal saline (ns-HES) and in balanced electrolyte solution (bal-HES) was evaluated in children with a focus on acid-base, electrolyte and hemoglobin changes.
METHODS: Following local ethics committee approval, pediatric patients aged up to 12 years with an ASA risk score of I-III undergoing perioperative administration of HES (ns-HES from May 2006 to December 2007, bal-HES from January 2008 to January 2009) were included. Patient demographics, the performed procedure, adverse drug reactions, hemodynamic data and the results of blood gas analysis were documented with a focus on changes in acid-base, electrolyte and hemoglobin concentrations.
RESULTS: Of 396 enrolled patients (ASA I-III; age 2.3 +/- 3, range day of birth - 12 years; body weight 10.8 +/- 9, range 0.9-52 kg), 249 received ns-HES and 147 bal-HES (mean volume infused 9.9 +/- 4 and 9.4 +/- 6.9 ml x kg(-1), respectively). After HES infusion, hemoglobin decreased in both groups, whereas bicarbonate and base excess (BE) decreased only with ns-HES and remained stable with bal-HES (BE before infusion: ns-HES -1.8 +/- 2.8, bal-HES -1.7 +/- 2.7 mmol x l(-1); after infusion: ns-HES -2.6 +/- 2.4; bal-HES -1.6 +/- 2.6 mmol x l(-1), P < 0.05). Chloride (Cl) concentrations increased in both groups and were significantly higher with ns-HES (Cl before infusion: ns-HES 105.6 +/- 3.7, bal-HES 105.1 +/- 2.8 mmol x l(-1); after infusion: ns-HES 107.7 +/- 3.2, bal-HES 106.3 +/- 2.9 mmol x l(-1), P < 0.01). No serious adverse drug reactions were observed.
CONCLUSION: Infusion related iatrogenic acid-base and electrolyte alterations can be minimized by using hydroxyethyl starch in a balanced electrolyte solution instead of normal saline.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19968805     DOI: 10.1111/j.1460-9592.2009.03197.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  4 in total

1.  Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study.

Authors:  Tim Philipp Simon; Tobias Schuerholz; Lars Hüter; Michael Sasse; Florian Heyder; Wolfgang Pfister; Gernot Marx
Journal:  Crit Care       Date:  2012-01-25       Impact factor: 9.097

2.  Effects of two different strategies of fluid administration on inflammatory mediators, plasma electrolytes and acid/base disorders in patients undergoing major abdominal surgery: a randomized double blind study.

Authors:  Carlo Alberto Volta; Alessandro Trentini; Lucia Farabegoli; Maria Cristina Manfrinato; Valentina Alvisi; Franco Dallocchio; Elisabetta Marangoni; Raffaele Alvisi; Tiziana Bellini
Journal:  J Inflamm (Lond)       Date:  2013-09-24       Impact factor: 4.981

3.  Current Trends in Volume Replacement Therapy and the Use of Synthetic Colloids in Small Animals-An Internet-Based Survey (2016).

Authors:  Ivayla D Yozova; Judith Howard; Nadja E Sigrist; Katja-Nicole Adamik
Journal:  Front Vet Sci       Date:  2017-09-04

4.  Low- versus High-Chloride Content Intravenous Solutions for Perioperative Patients: A Systematic Review and Meta-Analysis.

Authors:  Xuan Song; Huairong Wang; Xinyan Liu; Xiuyan Guo; Baiqing Yu; Nana Zhang
Journal:  Biomed Res Int       Date:  2021-01-02       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.